Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILIA phase 3 trial of tozorakimab in hospitalized patients with viral lung infection requiring supplemental oxygen
MOH_2023-04-19_012553Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Viral lower respiratory tract infection (VLRTI) comparing Tozorakimab + standard of care with Placebo + standard of care (2 arms). Started Apr 2023; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on MOH_2023-04-19_012553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-19_012553.